Abstract
Context: Hypophosphataemia after administration of ferric carboxymaltose (FeCXM), secondary to excessive urinary phosphate loss mediated by the fibroblastic growth factor 23 (FGF23), is generally asymptomatic, except when the deficiency is very severe. Case Description: A female patient undergoing bariatric surgery experienced, at an early stage vitamin D deficiency with secondary hyperparathyroidism, and, ten and thirteen years after, develop two episodes of severe ferropenia, for which she was administered FeCXM. In both cases develop severe hypophosphatemia coursing in a completely asymptomatic. Conclusion: Unless there is already a previous depletion of phosphorus, hypophosphataemia secondary to FeCXM should not be an obstacle to future administrations. Reusing FeCXM should only be performed when phosphatemia values have recovered.
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callMore From: Endocrinology&Metabolism International Journal
Disclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
